Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares tumbled nearly 11% in Wednesday’s trading session, as Wall Street came down hard on the drug maker. …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is scheduled to report its fourth-quarter earnings tomorrow morning, and H.C.
Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.
Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.
Salix Pharmaceuticals, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced today that the U.S.
Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
H.C.
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received CE Mark from the European Commission for the …
